Milestone Pharmaceuticals Advances CARDAMYST with FDA and Financial Boost

The latest announcement is out from Milestone Pharmaceuticals ( (MIST) ).

Milestone Pharmaceuticals announced that the FDA has accepted their response to the Complete Response Letter for CARDAMYST, setting a new PDUFA target date of December 13, 2025. The company has strengthened its financial position through a public equity offering, raising up to $170 million, and an amended royalty agreement with RTW Investments. These financial moves are aimed at supporting the potential commercial launch of CARDAMYST for PSVT, pending FDA approval, and maintaining operational momentum.

The most recent analyst rating on (MIST) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Milestone Pharmaceuticals stock, see the MIST Stock Forecast page.

Spark’s Take on MIST Stock

According to Spark, TipRanks’ AI Analyst, MIST is a Underperform.

Milestone Pharmaceuticals’ overall stock score reflects substantial financial difficulties, including no revenue and negative cash flows. However, the upcoming launch of CARDAMYST provides a potential turnaround opportunity, which is a significant positive factor. Technical indicators suggest a bearish trend, and valuation metrics highlight the lack of earnings and dividends, indicating a speculative investment.

To see Spark’s full report on MIST stock, click here.

More about Milestone Pharmaceuticals

Milestone Pharmaceuticals is a company operating in the pharmaceutical industry, focusing on the development and commercialization of innovative cardiovascular drugs. Their primary product, CARDAMYST (etripamil) Nasal Spray, targets the management of paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular rate (AFib-RVR).

Average Trading Volume: 1,380,937

Technical Sentiment Signal: Sell

Current Market Cap: $131.7M

Find detailed analytics on MIST stock on TipRanks’ Stock Analysis page.